I can extract side effects

The Kingdom of Isaac, Teva Pharmaceuticals headquarters.

CEO Schultz convened the heads of major laboratories and gathered for a meeting.

The secretary distributes a copy of the materials to all participants.

Schultz's face was full of clouds, and he said in a deep voice: "Everyone, please take a look at the information in your hand. It is the news sent back by the Teva Huaxia branch. Sanqing, the leading pharmaceutical company in the East, has launched Huaxia's first Gratin. Ray's generic."

Everyone was in an uproar and started talking one after another.

"Sanqing? Is it the Sanqing that develops anti-cancer drugs and AD specific drugs? It also wants to enter the field of generic drugs?"

"Glatiramer is our flagship product. The patent expired five years ago, which attracted the joint encirclement and suppression of two generic drug giants, Sandoz and Medelan. This has caused the company's stock price to plummet and has a great impact on the market. , if another pharmaceutical company with strong strength from the East is added, it will cause major damage to the company's sales."

"Damn it, the generic medicines from the East have always been known to be cheap, and they will have a huge impact on our original medicines."

"Why is Sanqing's generic drug as good in efficacy and quality as our original drug? It's unscientific."

"It seems that they have invested a lot of R\u0026D power in this to achieve such results. This will definitely take away a lot of our market."

"Sanqing wants money and technology, and it will be our enemy in the field of generic drugs."

Glatiramer is a first-line drug for the treatment of multiple sclerosis developed by Teva. It ranks 17th in the ranking of best-selling drugs in the world, and its sales have exceeded 4 billion US dollars for five consecutive years, ranking first in the list of multiple sclerosis drugs. It is a blockbuster drug in rare diseases.

The global multiple sclerosis drug market size is approximately USD 20 billion. And Eagle Country is the biggest market for the drug.

Multiple sclerosis is a chronic central nervous system (brain and spinal cord) disease that mostly occurs in young adults aged 20-40. The exact cause is unknown, and the international community believes that it is related to autoimmunity. The clinical manifestations are limb numbness, optic neuritis leading to vision loss or even blindness, and abnormal movement leading to difficulty in walking or even paralysis. The malignancy of this disease is comparable to neurotumors.

Schultz scanned the audience with falcon-like eyes, and slowly said: "The only good news is that due to the short time, this generic drug is mainly marketed in China, and has not yet been approved by the FDA. It has entered the Eagle Country market."

"Guys, you need to go all out and develop an upgraded product. The only thing we have to compete with cheap generics is the long-acting version of glatiramer, which is not enough."

"Sanqing's research and development strength is unquestionable, and it is at the top level in the world. Their move into the field of generic drugs will definitely set off a storm of blood."

"The global generic drug market needs to understand one thing: the wolf is coming."

"We have to make changes, just take advantage of the stock price drop, and carry out global layoffs. My plan is to lay off 10,000 employees first, reduce operating and management expenses, and then acquire new companies with complementary businesses after the stock price increases, so as to enrich our business. Product line, survive in the brutal competition."

The heads of the major laboratories nodded solemnly.

*****

Tianzhu Kingdom, Mengmai City, the headquarters of Sun Pharmaceutical.

Tianzhu is a magical country with an extremely developed generic drug industry, which not only meets the domestic demand for drugs, but also sells them overseas, firmly occupying 40% of Eagle Country's generic drug market.

Drugs with an original price of several thousand yuan, Tianzhu's generic drugs only cost a few hundred yuan, and drugs with an original price of several hundred yuan, Tianzhu's generic drugs can even be sold for a few yuan.

The reason why it is so cheap is that the production cost is low, and the government support ignores medical patents.

The government stands on the moral high ground, saying that if medicines are too expensive, people will die if they can’t afford them. Therefore, in order to save people’s lives, they allow imitation of foreign patented medicines.

As long as the production process of the generic drug is different from the original version, in other words, the original version cooks rice and adds water, and it cooks rice and adds soup, which can bypass the production process patent.

Therefore, even if the patented drug is still in the protection period, Tianzhu Pharmaceutical Company can openly infringe and imitate it, and Tianzhu Pharmaceutical Company always chooses the latest and most effective drug for imitation, which makes Ouying Pharmaceutical, which has invested a lot of research and development costs, hate it. Gritting teeth.

In addition to generic drugs, Tianzhu's medical level is also very high. Many wealthy people in developed countries will choose to go to Tianzhu for medical treatment, such as organ transplantation.

Even global pharmaceutical giants often set up branches in Tianzhu to conduct various clinical trials. After developing new drugs, they will license them to generic drug companies in Tianzhu at a low price as soon as possible.

Because the clinical cost of Tianzhu is very low, the requirements are also low, and it is convenient to recruit people to test drugs. Even if the other party is damaged by the test drugs, the compensation is very low. They all couldn't stop, so they acquiesced in this move, and each took what he wanted.

Tianzhu Kingdom is also very knowledgeable. Those generic drugs that infringe on patents will not be sold in developed countries, and the two parties have reached a tacit agreement with each other.

As a result, the generic drug industry in Tianzhu has flourished, and many generic drug giants have emerged.

Sun Pharmaceutical is the leader in the generic drug industry in Tianzhu Country, the fifth largest generic drug company in the world, and the number one Tianzhu pharmaceutical company in the Eagle Country market, with a total annual revenue of about 4 billion US dollars.

Although it is not as profitable as top pharmaceutical companies such as Pfizer, Bayer, Roche, and Novartis, it can still guarantee a 10% profit margin.

At this moment, Sanghavi, the president of Sun Pharmaceuticals, was sitting in his office at the headquarters, in a very bad mood.

It was a sunny day outside the window, but a storm was brewing in his heart.

The latest sales report was placed on the large desk, and the more he read it, the more angry he became.

There was a knock on the door, and several senior executives of the company rushed in. Looking at his gloomy face, they suddenly felt cold.

Sanghavi finally couldn't bear it anymore, and threw the report in his hand to the few people opposite, roaring loudly.

"Why are the sales of these generic drugs declining so much? I need an explanation!"

The sales director bit the bullet and said: "The main reason is that the sales of two generic drugs, Trexagliptin and Bosentan Tablets, have fallen sharply. As for the reason, it is because the oriental pharmaceutical giant Sanqing started to produce generic drugs, so we quickly lost the Chinese market."

The R\u0026D director picked up the report and read it carefully for a while, with a serious expression on his face.

"The patent of bosentan tablets has expired. There were no generic drugs in Huaxia before. They all bought our generic drugs, because the original drugs are expensive, 4,000 yuan a box, we only have more than 400 a box, but this Sanqing actually put The price has reached 300 yuan, which we really can't compare."

"There is also the long-acting hypoglycemic drug Trexagliptin of Takeda Pharmaceutical in Sakura Country, which has not applied for a patent in China, which also gave Sanqing an opportunity. Before the original drug, patients went to Sakura Country to buy it. A box of 5,000 yuan, our generic drug price is only 1,000 yuan, but this damn Sanqing actually lowered the price to 600 yuan, it is simply too much."

"There is no patent fee for these drugs, only the production cost. It is really unexpected that Sanqing can reduce the price to such a low level. I can't figure out why it is sold so low." The R\u0026D director looked puzzled and couldn't figure it out.

In their view, although generic drugs are cheap, they also have costs and they have to make money. Basically, it is enough to be more than half cheaper than the original drugs. There is really no need to drop them to such a low level, which is unreasonable.

"Moreover, the curative effect of Sanqing's generic drug is better than ours, reaching 100% of the effect of the original drug, and the side effects are also very small. The price is so cheap, it is simply outrageous. I can't imagine how they did it."

The more the R\u0026D director looked at it, the more frightened he was, with a look of disbelief.

Although Tianzhu Kingdom's generic drug technology is very strong, it cannot restore the efficacy of the original drug 100%.

This technology gap is really a bit big, and the price is not dominant, he finally understands why he lost the Chinese market.

Bosentan tablets are one of the main drugs for the treatment of rare pulmonary hypertension, which can effectively improve the exercise capacity of patients and reduce clinical deterioration. Like troxagliptin for the treatment of type II diabetes, there is no patent trouble. Its flagship generic drug is also very popular in the Eagle Country market.

Sanghavi pondered for a while before giving instructions expressionlessly.

"As an innovative pharmaceutical company, Sanqing must have strong research and development capabilities. It is not surprising that generic drugs have this performance. However, I heard that they are now focusing on imitating rare disease drugs and drugs that are not on the market in China, so it is not a blow to us. Too big, we have other opportunities."

"We want to avoid direct confrontation and sell more medicines such as Jisandai and HIV three-in-one. The patents of these medicines have not expired. According to the laws of China, Sanqing cannot be imitated, so our sales will not be affected. "

"As for the drugs whose patents have expired, we should try our best to be the first to imitate them, and then immediately promote the listing of Yingguo, do you understand?"

Everyone nodded, and their hearts became heavy.

They knew in their hearts that Sanqing would definitely not be satisfied with these two generic drugs, and would continue to gain ground in the generic drug market.

In the field of generic drugs, a lone wolf has come.

This industry is already highly competitive and the profits are meager. As a result, it is bound to experience a round of war and reshuffle the cards.

So, who will be the first unlucky ghost to fall?

I hope it won't be them Sun Pharmaceutical.